Related Experiment Video

Updated: Oct 1, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

Therapeutic strategies to halt renal fibrosis

Ling Yu1, Nancy A Noble, Wayne A Border

  • 1Fibrosis Research Laboratory, Division of Nephrology, University of Utah, 391 Chipeta Way, Salt Lake City, Utah, UT 84108, USA.

Current Opinion in Pharmacology
|April 16, 2002
PubMed

Insights

Angiotensin II blockade slows kidney disease progression but cannot halt fibrosis alone. Combining therapies, like antibodies to transforming growth factor beta, may be necessary to effectively treat renal fibrosis.

Area of Science:

  • Nephrology
  • Fibrosis Research
  • Translational Medicine

Background:

  • Angiotensin II blockade is a standard therapy for slowing renal disease progression.
  • Current treatments are insufficient to halt progressive renal fibrosis.
  • Emerging therapies show promise in preclinical models.

Purpose of the Study:

  • To evaluate the efficacy of single-agent therapies for renal fibrosis.
  • To explore the potential of combination therapies for halting renal fibrosis.
  • To assess the role of transforming growth factor beta antibodies in treating kidney fibrosis.

Main Methods:

  • Review of existing literature on anti-fibrotic therapies.
  • Analysis of data from animal studies on renal fibrosis.
  • Assessment of potential for human clinical trials.

Main Results:

  • Angiotensin II blockade alone does not stop progressive renal fibrosis.
  • Antibodies to transforming growth factor beta are a promising therapeutic strategy.
  • No single agent is likely to be sufficient to halt renal fibrosis.

Conclusions:

  • Combination therapies are likely required to effectively halt renal fibrosis.
  • Further research into combination anti-fibrotic strategies is warranted.
  • Translational studies are needed to confirm efficacy in human trials.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...